Nanopublication: RAxR-SBM3F

Full identifier: http://purl.org/np/RAxR-SBM3Fx8CLgwXu2VKDILw4z35Byof9ardrrzen5dk

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAxR-SBM3F comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAxR-SBM3F...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "entyvio is an integrin receptor antagonist indicated for adult ulcerative colitis uc 1 1 adult patients with moderately to severely active uc who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids inducing and maintaining clinical response inducing and maintaining clinical remission improving endoscopic appearance of the mucosa achieving corticosteroid free remission adult crohn s disease cd 1 2 adult patients with moderately to severely active cd who have had an inadequate response with lost response to or were intolerant to a tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids achieving clinical response achieving clinical remission achieving corticosteroid free remission entyvio vedolizumab is indicated for inducing and maintaining clinical response inducing and maintaining clinical remission improving the endoscopic appearance of the mucosa and achieving corticosteroid free remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids entyvio vedolizumab is indicated for achieving clinical response achieving clinical remission and achieving corticosteroid free remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAxR-SBM3F... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T15:26:41.400+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAxR-SBM3F... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAxR-SBM3F... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAxR-SBM3F... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
show references